5 employees
Neuramedy provides research on neurodegenerative disorders focused on alpha-synuclein and related mechanisms for Parkinson's disease.
2019
$6.4M
from 5 investors over 5 rounds
Neuramedy raised $6.4M on July 21, 2020
Investors: STIC Ventures, Hana Ventures and Industrial Bank of Korea
Neuramedy raised undisclosed on July 3, 2019
Investors: TIPS Town and Devsisters Ventures